Skip to main content
. Author manuscript; available in PMC: 2024 May 20.
Published in final edited form as: J Am Coll Cardiol. 2023 Nov 30;83(1):109–279. doi: 10.1016/j.jacc.2023.08.017
COR LOE RECOMMENDATIONS
1 B-R 1. In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function.1-6
2a B-R 2. In patients with symptomatic AF, rhythm control can be useful to improve symptoms.7-11
2a B-R 3. In patients with a recent diagnosis of AF (<1 year), rhythm control can be useful to reduce hospitalizations, stroke, and mortality.12-14
2a B-R 4. In patients with AF and HF, rhythm control can be useful for improving symptoms and improving outcomes, such as mortality and hospitalizations for HF and ischemia.15-19
2a B-NR 5. In patients with AF, rhythm-control strategies can be useful to reduce the likelihood of AF progression.20-27
2b C-LD 6. In patients with AF where symptoms associated with AF are uncertain, a trial of rhythm control (eg, cardioversion or pharmacological therapy) may be useful to determine what if any symptoms are attributable to AF.28-32
2b B-NR 7. In patients with AF, rhythm-control strategies may be useful to reduce the likelihood of development of dementia or worsening cardiac structural abnormalities.33-45